주의력결핍 과잉행동장애(ADHD) 시장 규모, 점유율, 성장 분석 : 약물 종류별, 환자 연령별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Global Attention Deficit Hyperactivity Disorder Market size was valued at USD 18.52 Billion in 2024 and is poised to grow from USD 19.73 Billion in 2025 to USD 32.85 Billion by 2033, growing at a CAGR of 6.52% during the forecast period (2026-2033).

The global market for attention deficit hyperactivity disorder (ADHD) is experiencing significant growth driven by increased awareness and diagnosis across various age groups. This evolving landscape is reshaping demand for a wide array of services, including pharmaceuticals, behavioral therapies, diagnostic tools, and digital therapeutics aimed at managing ADHD. Untreated ADHD symptoms impede productivity and overall quality of life, leading to economic challenges. The expansion of clinical guidelines and routine screening in educational and healthcare settings has elevated treatment accessibility. Notably, the surge in telehealth and digital solutions has improved patient access and early diagnosis, prompting pharmaceutical innovation and new business opportunities. Investments in evidence-based software and integrated care platforms support further market expansion and enhance treatment frameworks.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Attention Deficit Hyperactivity Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Attention Deficit Hyperactivity Disorder Market Segments Analysis

Global attention deficit hyperactivity disorder market is segmented by drug class, patient age, distribution and region. Based on drug class, the market is segmented into Stimulants and Non-Stimulants. Based on patient age, the market is segmented into Pediatric and Adult. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Attention Deficit Hyperactivity Disorder Market

The growing awareness surrounding Attention Deficit Hyperactivity Disorder (ADHD) is significantly driving the global market for diagnosis and treatment. Educational initiatives aimed at reducing stigma have led to heightened recognition of ADHD symptoms among parents, educators, and healthcare providers. This increased awareness results in a higher demand for assessments and referrals for treatment, underscoring the importance of early intervention. Consequently, healthcare systems are expanding their diagnostic capabilities, while providers are exploring a variety of treatment options. The rise in diagnoses fuels investments from both pharmaceutical and non-pharmaceutical sectors, promoting the development of therapies, support programs, and service delivery models to address the needs of this population effectively.

Restraints in the Global Attention Deficit Hyperactivity Disorder Market

The Global Attention Deficit Hyperactivity Disorder (ADHD) market faces significant challenges due to a scarcity of specialists and an uneven distribution of qualified mental health professionals. This imbalance hinders the confirmation of diagnoses and the long-term management of the condition, ultimately limiting market growth. Patients often encounter prolonged wait times, travel difficulties, and insufficient local services, which can disrupt both the initiation and continuity of their treatment. Consequently, caregivers may postpone seeking necessary care, leading to a diminished uptake of available therapies and reduced investment in supportive infrastructure. These ongoing access issues contribute to a significant number of individuals remaining undiagnosed or inadequately treated, further restraining market potential.

Market Trends of the Global Attention Deficit Hyperactivity Disorder Market

The Global Attention Deficit Hyperactivity Disorder (ADHD) market is experiencing a significant shift towards personalized digital therapeutics, which enhance treatment strategies through tailored behavioral coaching, cognitive training, and medication management. This evolving landscape leverages advanced digital health platforms and app-based interventions, integrating seamlessly into electronic health records and telecare systems to improve care continuity and patient engagement. Healthcare stakeholders, including payers and providers, are increasingly exploring value-based reimbursement models for evidence-backed digital solutions that demonstrate enhanced functional outcomes. Furthermore, developers are focusing on user-centered designs that effectively address co-occurring conditions and cater to diverse age groups, driving innovation and growth in the ADHD market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Attention Deficit Hyperactivity Disorder Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Stimulants
  • Atomoxetine
  • Guanfacine
• Non-Stimulants

Global Attention Deficit Hyperactivity Disorder Market Size by Patient Age & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Attention Deficit Hyperactivity Disorder Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Attention Deficit Hyperactivity Disorder Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Attention Deficit Hyperactivity Disorder Market Size & CAGR (2026-2033)

• North America (Drug Class, Patient Age, Distribution, Region)
  • US
  • Canada
• Europe (Drug Class, Patient Age, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Patient Age, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Patient Age, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Patient Age, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eli Lilly (Strattera)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Ritalin)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Takeda) - Vyvanse
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Concerta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Noven Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amphastar Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neos Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ironshore Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhodes Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aimmune Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Solanto Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KemPharm Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NLS Pharmaceutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations